The device was not returned for evaluation.A review of the lot history record revealed no manufacturing nonconformities that would have contributed to this complaint.Additionally, a review of the complaint history of the reported lot revealed no other similar complaints.The investigation was unable to determine a definitive cause for the reported difficulties.It may be possible that forward/pushing movement of the supera delivery system during stent deployment caused the stent to shorten; however, this could not be confirmed.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
It was reported that the procedure was performed to treat a lesion in the moderately calcified superficial femoral artery (sfa).A 5.5 x 200 mm armada 18 was advanced over a command guide wire to perform pre-dilatation.The 5.5 x 200 mm supera stent delivery system was advanced to the lesion and deployed; however, during deployment, the stent was compressed and did not fully cover the target lesion.A second 5.5 x 80 mm supera stent was then deployed, overlapping the first supera, covering the remaining lesion.Post procedure, the patient was in stable condition.No additional information was provided.
|